Clinical Reviews
The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
Eur Urol. - 2012 : 63(3):506-16
Botulinum neurotoxin A for male lower urinary tract symptoms.
Curr Opin Urol. - 2011 : Jan;21(1):13-21. Erratum in: Curr Opin Urol. 2011 May;21(3):265. Dosage error in article text.
Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
Eur Urol. - 2011 : Sep ; 60(3):527-35.
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Eur Urol. - 2011 : Oct ; 60(4):809-25.
Ejaculatory dysfunction (EjD) and its association with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and BPH treatments
Urology - 2009 : May 8. [Epub ahead of print]
Lower Urinary Tract Symptoms Revisited: A Broader Clinical Perspective
Eur. Urol. - 2008 : 54 ( 3), 563-569
Impact of medical treatments for benign prostatic hyperplasia on sexual function
BJU International - 2006 : 97 (s2), 34-38
Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)
Eur. Urol. 47 - 2005 : 824–837
Genitourinary diseases
Drug Discovery Today: Therapeutic Strategies Vol. 2, No. 1 - 2005 : pp 1-52
The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
Eur Urol. - : 2012 Sep 11, [Epub ahead of print]
